Axsome therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Axsome therapeutics Contact Number

Contact Us Axsome Therapeutics

3 hours ago Axsome.com Show details

Contact Us. AXSOME THERAPEUTICS, INC. 22 Cortlandt St., 16th floor New York, NY 10007 Phone: +1(212)332-3241 +1(212)332-3241 Fax: +1‍(‍2‍1‍2‍)‍3‍2‍0‍-‍0‍2‍4‍5 Email: [email protected]axsome.com

1. 22 Cortlandt St., 16th Floor, New York, NY 10007

Category: Contact SupportShow more

Axsome Therapeutics Crunchbase Company Profile & …

9 hours ago Crunchbase.com Show details

(212) 203-5072

Contact Email [email protected]axsome.com. Phone Number +1 (212) 203-5072. Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate.

Founded: 2012
Founder: Herriot Tabuteau

Category: Contact NumberShow more

Axsome Therapeutics: Expanding Treatment for CNS Conditions

3 hours ago Axsome.com Show details

Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS-14. Learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

Category: Contact NumberShow more

Axsome Therapeutics, Inc. Information Axsome

1 hours ago Rocketreach.co Show details

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines.

Category: Contact NumberShow more

Axsome Therapeutics Inc TheStreet

6 hours ago Thestreet.com Show details

212.332.3241

Address. 22 Cortlandt Street 16th floor, New York, NY 10007. Phone. 1.212.332.3241. Website. www.axsome.com. Axsome Therapeutics, Inc. engages …

Category: Contact NumberShow more

Axsome Therapeutics, Inc. Email Format axsome.com …

6 hours ago Rocketreach.co Show details

Axsome Therapeutics, Inc. Email Format. Axsome Therapeutics, Inc. uses 3 email formats, with first_initial last (ex. [email protected]axsome.com) being used 85.9% of the time. Get Verified Emails for Axsome Therapeutics, Inc. Employees. Axsome

Category: Contact NumberShow more

Axsome Therapeutics Company Profile Office Locations

6 hours ago Craft.co Show details

AXSOME THERAPEUTICS INVESTIGATION: Block & Leviton Investigates Axsome Therapeutics For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential …

Category: Contact NumberShow more

EX99.1

4 hours ago Sec.gov Show details

Exhibit 99.1 . Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy . NEW YORK, September 16, 2021 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in …

Category: Contact NumberShow more

Axsome Therapeutics, Inc. (AXSM) Company Profile & …

4 hours ago Finance.yahoo.com Show details

See the company profile for Axsome Therapeutics, Inc. (AXSM) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives

Category: Contact NumberShow more

Axsome says U.S. FDA asks for no extra data for depression

1 hours ago Metro.us Show details

(Reuters) -Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company’s drug to treat depression as the agency continues

Category: Contact NumberShow more

Axsome Therapeutics, Inc. (AXSM) Company Profile

6 hours ago Stockanalysis.com Show details

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment

Category: Contact NumberShow more

Axsome Therapeutics Announces FDA Acceptance of New Drug

3 hours ago Stocktitan.net Show details

212-332-3243

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]axsome.com www.axsome.com. View source version on GlobeNewswire.com

Category: Contact NumberShow more

Axsome Therapeutics, Inc. – Schall Law Firm

3 hours ago Schallfirm.com Show details

Axsome Therapeutics, Inc. Join Class Action » The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found deficiencies with its New Drug Application (NDA) for AXS-05.

Category: Contact NumberShow more

Investigation announced for LongTerm Investors in Axsome

3 hours ago Openpr.com Show details

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858

1. Author: Shareholders Foundation

Category: Contact NumberShow more

AXSOME THERAPEUTICS INVESTIGATION: Block & Leviton

3 hours ago Finance.yahoo.com Show details

BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. Investors who have lost money in their

1. Author: Block & Leviton LLP

Category: Contact NumberShow more

Axsome Therapeutics Inc. – Scott+Scott

6 hours ago Scott-scott.com Show details

844-818-6982

On this news, the price of Axsome shares fell 46.5% on August 9, 2021, to close at $27.37, down from the previous close price of $51.16. What You Can Do. If you purchased Axsome shares or securities, and you wish to discuss this investigation, please contact attorney Joe Pettigrew at 844-818-6982, or at [email protected]

Category: Contact NumberShow more

AXSM Axsome Therapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for …

Category: Contact NumberShow more

Axsome Therapeutics, Inc.: Rosen Law

2 hours ago Rosenlegal.com Show details

Axsome Therapeutics, Inc. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public.

Category: Contact NumberShow more

Axsome Therapeutics Inc. (AXSM) Latest News and Helpful

1 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 37.59 million. AXSM does have institutional investors; and they hold 61.80% of the stock. Axsome Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Category: Contact NumberShow more

Axsome Therapeutics Announces AXS12 Achieves Primary

3 hours ago Globenewswire.com Show details

Axsome will host a conference call and webcast with slides today at 8:00 AM Eastern to discuss the topline results of the CONCERT trial of AXS-12 in narcolepsy. To participate in the live

Category: Contact NumberShow more

Axsome Therapeutics Inc (AXSM) Up 1.85% in Premarket Trading

9 hours ago Investorsobserver.com Show details

Axsome Therapeutics Inc has a Long-Term Technical rank of 20. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 80% of the market scoring higher. In the Biotechnology industry which is number 135 by this metric, AXSM ranks better than 48% of stocks. Important Dates for Investors in AXSM:

Category: Contact NumberShow more

Is There Any Hope Left for Axsome Therapeutics? The

9 hours ago Fool.com Show details

1. 2019 was a good year for Axsome. It announced top-line clinical trial results on AXS-05 for the treatment of depression (phase 2), AXS-07 for the treatment of migraine headaches (phase 3), and AXS-12 for the treatment of narcolepsy (phase 2). Due to pandemic-related logistical issues, however, the company didn't file its new drug application for AXS-05 until April 2021. In the first quarter, Axsome burned through about $30 million, and ended the period with about $164.7 million on the books. Back in March 2020, AXS-05 failed to show statistically significant results in a phase 3 trial investigating its efficacy against treatment-resistant depression (which is differentiated from regular depression). On top of that, this month, the company announced that the U.S. Food and Drug Administration (FDA) had revoked its breakthrough therapy designation for AXS-12, citing the approval of a competitor's cataplexy in narcolepsy treatment.

Category: Contact NumberShow more

Axsome Therapeutics Stock (AXSM): PDUFA Ahead Seeking Alpha

2 hours ago Seekingalpha.com Show details

Axsome Therapeutics has a vast pipeline of CNS drugs. The company has a near-term catalyst, and the stock has shown its mettle earlier. Read more on …

Category: Contact NumberShow more

Axsome Therapeutics : Initiates SYMPHONY Phase 3 Trial of

7 hours ago Marketscreener.com Show details

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in SYMPHONY (Study Evaluating a Mechanistic Approach to Treating Narcolepsy), a Phase 3, randomized, …

Category: Contact NumberShow more

Axsome Therapeutics Announces AXS05 Achieves Primary and

6 hours ago Stocktitan.net Show details

212-332-3243

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]axsome.com www.axsome.com. View source version on GlobeNewswire.com

Category: Contact NumberShow more

Axsome Therapeutics Reports Second Quarter 2021 Financial

Just Now Presslasvegas.com Show details

Company to host conference call today at 8:00 AM Eastern. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June …

Category: Contact NumberShow more

Axsome Therapeutics : Reports Second Quarter 2021

5 hours ago Marketscreener.com Show details

Company to host conference call today at 8:00 AM Eastern. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June …

Category: Contact NumberShow more

Axsome Therapeutics Employees, Board Members, Advisors

6 hours ago Crunchbase.com Show details

Number of Employee Profiles 2 Axsome Therapeutics has 2 current employee profiles, including Founder, CEO & Chairman Herriot Tabuteau . Herriot …

Category: Contact NumberShow more

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest

2 hours ago Marketbeat.com Show details

Axsome Therapeutics, Inc. (NASDAQ:AXSM) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 3,350,000 shares, a decline of 16.5% from the August 31st total of 4,010,000 shares. Currently, 11.3% of the shares of the company are short sold. Based on an average daily volume of 1,250,000 shares, the …

Category: Contact NumberShow more

1 BeatenDown Stock With 10X Potential Nasdaq

1 hours ago Nasdaq.com Show details

Peak sales for this medicine could be between $500 million and $1 billion, according to the company. Axsome's potential treatment for narcolepsy, AXS-12, with peak annual sales of $1 billion, also

Category: Contact NumberShow more

Axsome Therapeutics Inc (AXSM) Up 2.32% in Premarket Trading

9 hours ago Investorsobserver.com Show details

Axsome Therapeutics Inc has a Long-Term Technical rank of 2. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 98% of the market scoring higher. In the Biotechnology industry which is number 131 by this metric, AXSM ranks better than 4% of stocks. Important Dates for Investors in AXSM:

Category: Contact NumberShow more

Axsome Therapeutics Announces FDA Acceptance of New Drug

4 hours ago Drugs.com Show details

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-07

Category: Contact NumberShow more

Investigation announced for Investors in shares of Axsome

3 hours ago Openpr.com Show details

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858

1. Author: Shareholders Foundation

Category: Contact NumberShow more

Axsome Therapeutics Announces $225 Million Term Loan

4 hours ago Globenewswire.com Show details

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital and the number or type of studies or nature of results necessary to …

Category: Contact NumberShow more

AXSM: Dividend Date & History for Axsome Therapeutics Inc

5 hours ago Dividend.com Show details

Axsome Therapeutics Inc Dividend policy None Price as of: OCT 04, 12:00 PM EDT $32.63 -1.65 0% Dividend (Fwd) Consecutive Years of Dividend Increase is the number of years in a row in which there has been at least one payout increase and no payout decreases. Contact us About us FAQ DARS Ratings

Category: Contact NumberShow more

Corporate Presentation UBS Global Healthcare Conference

1 hours ago Axsometherapeuticsinc.gcs-web.com Show details

3 For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life -changing medicines.

Category: Contact NumberShow more

An Evaluation of AXS05 for the Treatment of TRD in

7 hours ago Clinicaltrials.gov Show details

Axsome Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04971291 Other Study ID Numbers: AXS-05-TRD-203 : First Posted: July 21, 2021 Key Record Dates: Last Update Posted: July 26, 2021 Last Verified: July 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No

Category: Contact NumberShow more

Axsome (AXSM) Begins LateStage Sleep Disorder Study on

3 hours ago Nasdaq.com Show details

Sep 17, 2021 10:05AM EDT. Axsome Therapeutics, Inc. AXSM announced that it has initiated enrollment in the phase III study — SYMPHONY — which will evaluate its pipeline candidate, AXS-12, in

Category: Contact NumberShow more

Axsome Therapeutics, Inc. hiring Quality Systems

7 hours ago Linkedin.com Show details

Axsome Therapeutics is currently searching for a Quality Systems Specialist / Manager. DESCRIPTION. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the

Category: Contact NumberShow more

Axsome Therapeutics Announces AXS05 Achieves Primary and

3 hours ago Benzinga.com Show details

About Axsome Therapeutics, Inc. and the number or type of studies or nature of results necessary to support the filing of a new drug application ("NDA") for …

Category: Contact NumberShow more

Axsome Therapeutics Inc. (AXSM) Stock is risk free for

2 hours ago Bovnews.com Show details

Currently, 21.47 percent of Axsome Therapeutics Inc. shares are owned by insiders, and 61.30 percent are held by financial institutions. Coleman Mark, the Director at Axsome Therapeutics Inc. (AXSM) has bought 500 shares of firm on May 12 at a price of $58.15 against the total amount of $29075.0. >> 7 Top Picks for the Post-Pandemic Economy

Category: Contact NumberShow more

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus

1 hours ago Marketbeat.com Show details

Axsome Therapeutics has a 12 month low of $19.38 and a 12 month high of $87.24. Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Sunday, August 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.02. On average, research analysts predict that Axsome Therapeutics will post

Category: Contact NumberShow more

Axsome Therapeutics Reports Second Quarter 2021 Financial

7 hours ago Biospace.com Show details

Company to host conference call today at 8:00 AM Eastern. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June …

Category: Contact NumberShow more

Stock Summary TD Ameritrade

1 hours ago Research.tdameritrade.com Show details

21) 11.54

The number of shares of a security that have been sold short by investors. It is typically expressed as a percentage of the total number of shares outstanding and is reported on a monthly basis. (% of float 09/15/21) 11.54. 1d 2d 5d 1mo 3mo 6mo 1yr 3yr. DJIA S&P 500 NASDAQ SMA (50)

Category: Contact NumberShow more

Axsome Therapeutics Expands Term Loan Facility with

4 hours ago Financialpost.com Show details

212-332-3243

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]axsome.com www.axsome.com Share this article in your social network

Category: Contact NumberShow more

Axsome Therapeutics Expands Term Loan Facility with

3 hours ago Menafn.com Show details

212-332-3243

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: Tags axsome CNS Hercules

Category: Contact NumberShow more

An InDepth Look At The Axsome Therapeutics Inc. (AXSM

Just Now Marketingsentinel.com Show details

Insiders own 21.40% of the company shares, while shares held by institutions stand at 61.43% with a share float percentage of 78.15%. Investors are also buoyed by the number of investors in a company, with Axsome Therapeutics Inc. having a total of 256 institutions that hold shares in the company.

Category: Contact NumberShow more

What’s Happening With Axsome Therapeutics Stock? The US

Just Now Theusexpressnews.com Show details

21D: AXSM 38%, vs. S&P500 -2.9%; Outperformed market (10% likelihood event; 59% probability of rise over next 21 days) Axsome Therapeutics stock rose 38% the last twenty-one trading days (one month), compared to broader market (S&P500) decline of 2.9%; A change of 38% or more over twenty-one trading days is a 10% likelihood event, which has occurred …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes